Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LATS1 | O95835 | 1/20 | 0.42 |
| ▸ | CCNC | P24863 | 13/20 | 0.38 |
| ▸ | CDK8 | P49336 | 13/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.36 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.36 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17615772 | 0.84 | LATS1 (0.40) | LATS1CCNCCDK8KDM4CAURKA | |
| SCHEMBL17615605 | 0.80 | CCNC (0.48) | LATS1CCNCCDK8KDM4C | |
| SCHEMBL22163336 | 0.80 | KDM4C (0.50) | KDM4C | |
| SCHEMBL19268160 | 0.77 | KDM4C (0.42) | KDM4C | |
| SCHEMBL20724154 | 0.76 | KDM4C (0.55) | KDM4C | |
| SCHEMBL22163584 | 0.76 | KDM4C (0.59) | KDM4C | |
| SCHEMBL17898316 | 0.74 | KDM4C (0.55) | KDM4C | |
| SCHEMBL19268158 | 0.74 | EGFR (0.43) | KDM4C | |
| SCHEMBL19268159 | 0.73 | KDM4C (0.43) | KDM4C | |
| SCHEMBL19268156 | 0.73 | EGFR (0.38) | KDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170240546-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-08-24 | — | — | US | disclosed |
| US-20170240546-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240546-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5C | LATS1 4166/4885CCNC 1222/4885CDK8 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.